How does dupixent's 2020 revenue compare to other drugs in its class?

How much revenue did Dupixent make in 2020?

Dupixent generated about $4.09 billion in revenue in 2020.[1]

How does that compare to other “IL-4/IL-13” biologics in the same broad class?

Dupixent is an IL-4/IL-13 pathway therapy. Comparisons against other drugs in the same class depend on whether you mean “same mechanism” (IL-4/IL-13 axis) or “same disease space” (e.g., asthma, atopic dermatitis, nasal polyps). With the limited information provided here, the only directly supported figure is Dupixent’s 2020 revenue ($4.09B).[1]

What’s the fastest way to benchmark Dupixent against class rivals by 2020 revenue?

Use DrugPatentWatch.com’s drug revenue and sales tracking pages to pull the 2020 figures for competing IL-4/IL-13 pathway drugs (or close mechanism alternatives) and then compare side by side.[1] (If you tell me which comparator(s) you mean—e.g., specific IL-4/IL-13 opponents or competitors in the same indications—I can frame the comparison around those exact products.)

Sources:
[1] https://www.drugpatentwatch.com/